Breaking News Instant updates and real-time market news.

RHHBY

Roche

$29.71

-0.07 (-0.24%)

12:32
10/14/16
10/14
12:32
10/14/16
12:32

FDA approves Genentech's Lucentis prefilled syringe

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration approved the Lucentis, ranibizumab injection, 0.5 mg prefilled syringe, PFS, as a new method of administering the medicine. Like the Lucentis 0.5 mg vial, the 0.5 mg PFS is approved to treat people with wet age-related macular degeneration, AMD, and macular edema after retinal vein occlusion, RVO.The Lucentis PFS is the first syringe prefilled with an anti-VEGF medicine FDA-approved to treat two eye conditions. "The FDA approval of the Lucentis prefilled syringe marks a new milestone in our ongoing commitment to people affected by vision-threatening eye diseases," said Sandra Horning, M.D., chief medical officer and head of Global Product Development. "With the PFS, physicians will have a new option for administering Lucentis to the hundreds of thousands of people in the U.S. diagnosed with either wet AMD or macular edema after RVO." The Lucentis PFS allows physicians to eliminate several steps in the preparation and administration process, including disinfecting the vial, attaching a filter needle, drawing the medicine from the vial using the needle, removing the filter needle from the syringe and replacing with an injection needle. With the Lucentis PFS, physicians attach the injection needle to the syringe and adjust the dose prior to administration. The Lucentis 0.5 mg PFS is expected to be available in early 2017.

  • 19

    Oct

  • 06

    Nov

  • 10

    Nov

RHHBY Roche
$29.71

-0.07 (-0.24%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.

TODAY'S FREE FLY STORIES

PSTG

Pure Storage

$12.16

-0.17 (-1.38%)

14:12
12/09/16
12/09
14:12
12/09/16
14:12
Conference/Events
Pure Storage participates in a conference call with Stifel »

Stifel's Equity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

  • 12

    Jan

  • 13

    Jan

  • 09

    Dec

IX

ORIX Corp

$82.04

0.99 (1.22%)

14:10
12/09/16
12/09
14:10
12/09/16
14:10
Upgrade
ORIX Corp rating change  »

ORIX Corp upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIG

Transocean

$15.43

0.585 (3.94%)

14:10
12/09/16
12/09
14:10
12/09/16
14:10
Options
Transocean short-term puts active as shares see strength »

Transocean short-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

NMR

Nomura

$6.70

0.22 (3.40%)

14:08
12/09/16
12/09
14:08
12/09/16
14:08
Upgrade
Nomura rating change  »

Nomura upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MET

MetLife

$57.13

-0.06 (-0.10%)

14:06
12/09/16
12/09
14:06
12/09/16
14:06
Downgrade
MetLife rating change  »

MetLife downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

14:05
12/09/16
12/09
14:05
12/09/16
14:05
General news
Treasury Action: next week's auctions could be difficult »

Treasury Action: next…

QQQ

NASDAQ 100 Index Tracking Stock

$118.57

0.21 (0.18%)

14:00
12/09/16
12/09
14:00
12/09/16
14:00
Options
Bullish yearend play in the PowerShares QQQ ETF »

Bullish yearend play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:50
12/09/16
12/09
13:50
12/09/16
13:50
General news
Action Economics Survey results: equities continue to charge ahead »

Action Economics Survey…

CFX

Colfax

$39.04

-0.245 (-0.62%)

13:49
12/09/16
12/09
13:49
12/09/16
13:49
Conference/Events
Colfax to hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

13:45
12/09/16
12/09
13:45
12/09/16
13:45
General news
FX Action: USD-JPY »

FX Action: USD-JPY moved…

NRE

Northstar Realty Europe Corp.

$12.13

0.36 (3.06%)

, NSAM

NorthStar Asset Management

$15.09

0.09 (0.60%)

13:44
12/09/16
12/09
13:44
12/09/16
13:44
Hot Stocks
Bow Street confirms $13 per share offer for Northstar Realty Europe Corp. »

Bow Street, which holds a…

NRE

Northstar Realty Europe Corp.

$12.13

0.36 (3.06%)

NSAM

NorthStar Asset Management

$15.09

0.09 (0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

CALA

Calithera Biosciences

$3.20

-0.05 (-1.54%)

13:44
12/09/16
12/09
13:44
12/09/16
13:44
Conference/Events
Calithera Biosciences to hold a conference call »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

BAC

Bank of America

$23.03

0.075 (0.33%)

13:40
12/09/16
12/09
13:40
12/09/16
13:40
Options
Eight year highs and flat skew draw ratio call spreader in Bank of America »

Eight year highs and flat…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jan

VIA

Viacom

$42.60

0.45 (1.07%)

, VIAB

Viacom

$38.80

0.79 (2.08%)

13:37
12/09/16
12/09
13:37
12/09/16
13:37
Hot Stocks
Box Office Battle: 'Office Christmas Party' looks to topple 'Moana' »

Opening this weekend, and…

VIA

Viacom

$42.60

0.45 (1.07%)

VIAB

Viacom

$38.80

0.79 (2.08%)

CMCSK

Comcast

CMCSA

Comcast

$69.23

-0.1 (-0.14%)

SNE

Sony

$29.40

0.24 (0.82%)

FOXA

21st Century Fox

$28.64

0.53 (1.89%)

FOX

21st Century Fox

$28.48

0.53 (1.90%)

DIS

Disney

$103.84

0.46 (0.44%)

TWX

Time Warner

$94.89

0.34 (0.36%)

LGF

Lionsgate

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VHC

VirnetX

$2.95

-0.35 (-10.61%)

, AAPL

Apple

$112.12

1.09 (0.98%)

13:32
12/09/16
12/09
13:32
12/09/16
13:32
Hot Stocks
VirnetX says U.S. Federal Circuit Appeals Court issued three appeal decisions »

VirnetX announced that on…

VHC

VirnetX

$2.95

-0.35 (-10.61%)

AAPL

Apple

$112.12

1.09 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

AFL

Aflac

$68.79

-0.83 (-1.19%)

13:25
12/09/16
12/09
13:25
12/09/16
13:25
Options
AFLAC call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
12/09/16
12/09
13:25
12/09/16
13:25
General news
Energy Action: Weekly Baker-Hughes rig count »

Energy Action: Weekly…

TTI

TETRA

$4.61

-0.4 (-7.98%)

13:20
12/09/16
12/09
13:20
12/09/16
13:20
Downgrade
TETRA rating change  »

TETRA downgraded on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

$NYE

NYSE Market Internals

13:16
12/09/16
12/09
13:16
12/09/16
13:16
Technical Analysis
NYSE market internals summary »

Breadth is mixed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

13:16
12/09/16
12/09
13:16
12/09/16
13:16
Technical Analysis
NASDAQ market internals summary »

Volume is extremely heavy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$225.83

0.68 (0.30%)

, XLF

Financial Select Sector

$23.64

-0.06 (-0.25%)

13:13
12/09/16
12/09
13:13
12/09/16
13:13
Technical Analysis
On The Fly: ETF fund flow highlights »

The week saw very large…

SPY

SPDR S&P 500 ETF Trust

$225.83

0.68 (0.30%)

XLF

Financial Select Sector

$23.64

-0.06 (-0.25%)

XLP

Consumer Staples Sector SPDR

$51.86

0.56 (1.09%)

XLI

Industrial Select Sector SPDR

$63.87

0.18 (0.28%)

VOO

Vanguard S&P 500 ETF

$207.39

0.65 (0.31%)

JNK

SPDR Barclays High Yield Bond

$36.47

0.0085 (0.02%)

IEMG

iShares Core MSCI Emerging Markets

$43.94

-0.165 (-0.37%)

QQQ

NASDAQ 100 Index Tracking Stock

$118.57

0.21 (0.18%)

USO

United States Oil Fund

$11.42

0.11 (0.97%)

XOP

SPDR Oil Exploration and Production Fund

$43.19

-0.16 (-0.37%)

UWTI

VelocityShares 3x Long Crude Oil ETN

IBB

iShares Nasdaq Biotechnology Index

$268.52

2.24 (0.84%)

GLD

SPDR Gold Trust

$110.63

-0.94 (-0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTI

TETRA

$4.61

-0.4 (-7.98%)

13:12
12/09/16
12/09
13:12
12/09/16
13:12
Downgrade
TETRA rating change  »

TETRA downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

IRM

Iron Mountain

$34.71

-0.28 (-0.80%)

13:11
12/09/16
12/09
13:11
12/09/16
13:11
Hot Stocks
Iron Mountain receives approval to sell C21 to Oasis Group »

Iron Mountain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$289.54

4.24 (1.49%)

13:10
12/09/16
12/09
13:10
12/09/16
13:10
Hot Stocks
Biogen off highs after disclosing serious adverse event in Alzheimer's trial »

Shares of Biogen are well…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$29.28

0.63 (2.20%)

13:10
12/09/16
12/09
13:10
12/09/16
13:10
Options
MGM calls active as shares move off session highs »

MGM calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.